KEARNEY
11.5.2023 10:40:25 CEST | Business Wire | Press release
Leading global consultancy partnership Kearney has today released new data showing revenue predictions and sentiment from senior telecommunications and consumer goods lead around the metaverse. The report also reveals that many senior leaders are still unsure what form this will take and how this will affect their businesses’ bottom lines.
The Pragmatic Leader’s Guide to the Metaverse reveals that a quarter of European consumer goods and telco leaders (25%) expect to see the metaverse account for revenues of between 5-20% by 2025, rising to more than half (52%) who expect this revenue by 2030. However, exactly how to monetise these emerging concepts remains unclear, constituting a real problem for many leaders, with 84% of telecom leaders and 64% of consumer goods leaders agreeing that companies will need to expand into new markets and channels to ensure relevance in the space.
At the higher end, almost one in 10 (9%) leaders in Europe expect between 20-50% of revenue to originate from the metaverse by 2030.
The Guide draws on qualitative analysis, leveraging insights from 167 senior telecoms and consumer goods decision-makers in companies with 1,000 to 50,000+ employees across Asia Pacific, North America and Europe.
Compared to Europe, only 10% of respondents in North America predicted that between 5-20% of revenue would stem from the metaverse by 2025. This figure then rises to 45% of respondents predicting this level of revenue by 2030.
Overall, 56% of consumer goods leaders and 59% of telco leaders in Europe see the metaverse as having a positive impact on their industry. However, one in four (24%) telco leaders were ‘very’ positive about the metaverse’s impact compared to only 3% of consumer goods professionals, showing that sentiment is still highest in the technology and communications space.
One of the biggest risks leaders associated with the metaverse was cybersecurity, with 57% of telco respondents and 63% of consumer goods European respondents citing this as a high impact risk to the metaverse. Interestingly, regulatory risk was also considered ‘high impact’ by 43% of telco respondents and 27% of consumer goods respondents.
Jesper Larsson, Partner at Kearney, comments:
“Global leaders clearly see the metaverse as a true avenue of growth over the next five to ten years, with some predictions suggesting significant levels of revenue could originate in this virtual marketplace. The key challenge, however, will be how to monetise the platform as a revenue stream.”
“Technologies enabling and supporting the use of the metaverse, such as 5G, could offer potential to overcome this monetisation challenge. Such technologies would support an increased flow of data and satisfy demand, building out the capability of this platform even as they make it more profitable. Indeed, the metaverse could be the very use case that 5G has been waiting on, to realise its true potential.”
Eric Gervet, Partner at Kearney, adds:
Where once we had been seeing positive global sentiment towards the use of the metaverse as a platform for growth and revenue, inflation and global economic slowdown have put tension on the Tech sector, which requires companies to make trade-offs and pace investments. Doubling down on AI and optimizing EBITDA has become a short-term priority versus longer term investments, at least for the very short term.”
“Companies that act now to develop a strategy for how the growth of the metaverse could impact their model will have a significant advantage over the competition in deciding which technologies, partnerships and investments will be necessary to access this revenue stream.”
ENDS
Notes to Editors
Methodology
In light of the hype surrounding the metaverse, our primary research was designed to provide a comprehensive and nuanced understanding of its potential impact on businesses and the overall readiness for the metaverse. We surveyed 167 industry leaders from Asia Pacific, North America, and Europe who hold influential positions as business executives in the telecom or consumer goods sectors. Participants were required to be currently employed at companies with a minimum of 1,000 employees and hold a position within three degrees of separation from the CEO.
About Kearney
Kearney is a leading global management consulting firm. For nearly 100 years, we have been the trusted advisor to C-suites, government bodies, and nonprofit organizations. Our people make us who we are. Driven to be the difference between a big idea and making it happen, we help our clients break through. www.kearney.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
